EuBiologics Valuation

Q: What is the Fair Price of A206650 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A206650 (₩13150) is trading below our estimate of [[fair value]] (₩37369.9)

Is A206650 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A206650 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A206650 (₩13150) is trading below our estimate of fair value (₩37369.9)

Significantly Below Fair Value: A206650 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A206650?

Key metric: As A206650 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A206650. This is calculated by dividing A206650's market cap by their current revenue.
What is A206650's PS Ratio?
PS Ratio	6.9x
Sales	₩69.37b
Market Cap	₩480.43b

A206650 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.9x
Enterprise Value/EBITDA	28.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A206650's PS Ratio compare to its peers?

The above table shows the PS ratio for A206650 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5x
A064550 Bioneer	1.8x	23.5%	₩522.7b
A290650 L&C BIOLTD	5.1x	n/a	₩365.9b
A005250 Green Cross Holdings	0.3x	n/a	₩644.5b
A115450 HLB TherapeuticsLtd	13x	n/a	₩782.1b
A206650 EuBiologics	6.9x	21.9%	₩480.4b

Price-To-Sales vs Peers: A206650 is expensive based on its Price-To-Sales Ratio (6.9x) compared to the peer average (5x).

Price to Sales Ratio vs Industry

How does A206650's PS Ratio compare vs other companies in the KR Biotechs Industry?

27 Companies	Price / Sales	Estimated Growth	Market Cap
A006280 GC Biopharma	0.9x	8.8%	US$1.07b
A096530 Seegene	2.7x	14.5%	US$734.93m
A086900 Medy-Tox	3.6x	12.5%	US$634.10m
A005250 Green Cross Holdings	0.3x	n/a	US$462.72m

27 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A206650 is good value based on its Price-To-Sales Ratio (6.9x) compared to the KR Biotechs industry average (8.8x).

Price to Sales Ratio vs Fair Ratio

What is A206650's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A206650 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	6.9x
Fair PS Ratio	3.6x

Price-To-Sales vs Fair Ratio: A206650 is expensive based on its Price-To-Sales Ratio (6.9x) compared to the estimated Fair Price-To-Sales Ratio (3.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩273,500.00

0.9%

75.3%

J2KBIO

₩52.9b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,260.00

-5.8%

n/a

Medy-Tox

₩883.1b

Operates as a biopharmaceutical company in South Korea.

A086900

₩131,200.00

1.7%

-39.0%